An experimental cancer vaccine reduced the risk of death by 41% in a pivotal late-stage trial for acute myeloid leukemia, according to data released on Tuesday.
The Phase 3 REGAL trial evaluated galinpepimut-S, or GPS, as a maintenance treatment for patients in second or later complete remission who were ineligible for a stem cell transplant. Developed from four peptides targeting the WT1 protein found in leukemia cells, the off-the-shelf vaccine delivered a median overall survival of 24.0 months compared to 14.7 months for patients receiving the best available investigator-selected therapy.
Acute myeloid leukemia is an aggressive blood cancer that frequently returns after initial therapy, leaving patients with severely restricted treatment options. According to the American Cancer Society, around 22,720 people will likely be diagnosed with acute myeloid leukemia and around 11,500 are expected to die from the disease in 2026, with the condition accounting for one out of three leukemias in adults.
“Those patients don't have any good therapy options, and that's where the current vaccine trial is placed to provide a benefit,” Dr. Ravi Majeti, a Stanford professor of medicine who was independent of the trial, told The Washington Post.

The study met its primary endpoint of overall survival with a hazard ratio of 0.59 and a two-sided p-value of 0.035, resting on 80 deaths among 126 patients, or 63.5% of the trial population. Memorial Sloan Kettering Cancer Center researcher David A. Scheinberg invented the peptide vaccine over two decades of research into WT1-targeted immunotherapy, holding the Vincent Astor Chair at the institution.
The magnitude of the survival benefit observed with our investigational GPS cancer vaccine immunotherapy represents a defining milestone for Sellas and provides phase 3 validation of our WT1-targeted immunotherapeutic technology.
Angelos Stergiou, M.D., Sellas CEO, via Fierce Biotech
Hours after the trial results crossed the wire, Sellas Life Sciences commenced an underwritten public offering of $150.0 million in common stock.
The New York-based biopharmaceutical company also granted underwriters a 30-day option to purchase up to an additional $22.5 million of shares, with Morgan and TD Cowen acting as the joint book-running managers for the offering made pursuant to a shelf registration statement on Form S-3 filed with the Securities and Exchange Commission on March 20, 2026.
$SLS +300% (Market cap: ~$6B) Sellas Life Sciences' experimental cancer vaccine extended survival in a pivotal Phase 3 leukemia trial, meeting its primary endpoint. Its vaccine, galinpepimut-S (GPS), reduced the risk of death by 41% compared with the best available treatment in… pic.twitter.com/ApAngqbE9U
Sellas stock surged 156% to close at $19.15 on Tuesday, marking its best single-session gain in nearly six years.
With the primary endpoint secured, company leadership is preparing for discussions with federal regulators regarding an accelerated filing strategy. Sellas plans to submit a Biologics License Application in the first half of 2027 to seek approval for maintenance treatment in the patient population studied in the REGAL trial, following an orphan drug designation granted by the agency in 2023.
“We will evaluate every path available to us that is in the best interest of maximizing the value of GPS and SELLAS. Today's phase III readout transforms our strategic position,” Sellas CEO Angelos Stergiou said.

Independent medical observers urge caution while awaiting the full dataset, noting that open-label trial designs require careful scrutiny.
Earlier coverage: Cambridge Researchers Find Cancer-Driving Mutations Decades Before Symptoms